MedTrace Logo

The Safety of Proctofoam-HC in the Third Trimester of Pregnancy

NCT00405288 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 408

Last updated 2014-02-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the fetal safety of topical application of Proctofoam-HC®, an antihemorrhoidal, in the third trimester of pregnancy.

Conditions

Interventions

DRUG

Proctofoam-HC®

Observational study of the exposure to Proctofoam-HC®

Sponsors & Collaborators

  • Duchesnay Inc.

    collaborator INDUSTRY

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Gideon Koren, MD · The Hospital for Sick Children, Toronto Canada

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-11-30
Completion
2010-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00405288 on ClinicalTrials.gov